Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections – Drugs In Development, 2021, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.Epstein-Barr virus (EBV) or human herpes virus 4 virus is a member of the Herpesviridae family. It is one of the most common human viruses to cause cancer in humans and is associated with a wide range of human cancers originating from epithelial cells, lymphocytes and mesenchymal cells. It spreads most commonly through bodily fluids. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Treatment includes over-the-counter pain and fever medications to get relief from the symptoms of the disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 2, 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 10, 8, 7 and 5 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).- The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Advenchen Laboratories LLC

AlloVir Inc

Atara Biotherapeutics Inc

Boryung ViGenCell Inc

Bristol-Myers Squibb Co

China Immunotech Co Ltd

Citranvi Biosciences LLC

Elicio Therapeutics Inc

Eutilex Co Ltd

Galenbio Ltd

Geneius Biotechnology Inc

Genocea Biosciences Inc

iCELL Biotechnology Co Ltd

Immunotech Biopharm Ltd

Incyte Corp

Innovent Biologics Inc

Karyopharm Therapeutics Inc

Lion TCR Pte Ltd

ManysmarT Therapeutics Inc

Moderna Inc

Omeros Corp

Oxford Vacmedix UK Ltd

Replicate Bioscience Inc

Savoy Pharmaceuticals Inc

Shanghai YaKe Biotechnology Co Ltd

Viracta Therapeutics Inc

Vironika LLC

ViroStatics SRL

Table of Contents

Table of Contents

Introduction

Epstein-Barr Virus (HHV-4) Infections - Overview

Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development

Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment

Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development

Epstein-Barr Virus (HHV-4) Infections - Drug Profiles

Epstein-Barr Virus (HHV-4) Infections - Dormant Projects

Epstein-Barr Virus (HHV-4) Infections - Discontinued Products

Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Number of Products under Development by Universities/Institutes, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Products under Development by Universities/Institutes, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Advenchen Laboratories LLC, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by AlloVir Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Atara Biotherapeutics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Boryung ViGenCell Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Bristol-Myers Squibb Co, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by China Immunotech Co Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Citranvi Biosciences LLC, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Elicio Therapeutics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Eutilex Co Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Galenbio Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Geneius Biotechnology Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Genocea Biosciences Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by iCELL Biotechnology Co Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Immunotech Biopharm Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Incyte Corp, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Innovent Biologics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Karyopharm Therapeutics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Lion TCR Pte Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by ManysmarT Therapeutics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Moderna Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Omeros Corp, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Oxford Vacmedix UK Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Replicate Bioscience Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Savoy Pharmaceuticals Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Viracta Therapeutics Inc, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by Vironika LLC, 2021

Epstein-Barr Virus (HHV-4) Infections – Pipeline by ViroStatics SRL, 2021

Epstein-Barr Virus (HHV-4) Infections – Dormant Projects, 2021

Epstein-Barr Virus (HHV-4) Infections – Dormant Projects, 2021 (Contd..1)

Epstein-Barr Virus (HHV-4) Infections – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports